AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback